Senior Director, Corporate Counsel (12 month FTC)
13 hours ago
Oxford
Company description: OXB is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient's cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients' cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Job description: Join Us in Changing Lives At OXB , our people are at the heart of everything we do. We're on a mission to enable life-changing therapies to reach patients around the world—and we're looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful . We're currently recruiting for a Senior Director, Corporate Counsel to join our Legal team on a 12 month fixed-term contract . In this role, you will provide legal advice on corporate and company secretarial matters, partnering with the Chief Legal Officer to protect the Group, enable delivery of its strategy and maintain high standards of legal compliance playing a key part in advancing our mission and making a real difference. Your responsibilities in this role would be, inter alia, to: Assist CLO and Deputy Co Sec with annual report/interims/corporate updates Assist with FTSE listing requirements and FCA filings Assist with Group subsidiary management Assist with corporate governance compliance with best practice Assist with management of debt financing Assist with any corporate transactions, to the extent required Assist with Data Subject Access Requests We are looking for: Qualified solicitor in England and Wales holding a current practising certificate or equivalent professional standing Proven post-qualification experience gained in a leading law firm and/or a complex listed or regulated organisation. UK corporate law expertise with experience in governance, capital markets, M&A, compliance and managing complex legal matters Ability to translate complex legal and regulatory developments into practical, risk-based advice and effective organisational controls. About Us: OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors, the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing development and manufacturing expertise for lentiviral, AAV, adenoviral, MVA and other viral vectors. Building on its viral vector leadership, OXB also supports the development of emerging in vivo therapies through its expertise in vector engineering, manufacturing platforms, and novel envelope technologies. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Why Join Us? ?? Competitive total reward packages ?? Wellbeing programmes that support your mental and physical health ?? Career development opportunities to help you grow and thrive ?? Supportive, inclusive, and collaborative culture ?? State-of-the-art labs and manufacturing facilities ?? A company that lives its values: Responsible, Responsive, Resilient, Respect We want you to feel inspired every day. At OXB, we're future-focused and growing fast. We succeed together—through passion, commitment, and teamwork. Ready to Make a Difference? Collaborate. Contribute. Change lives. Profile description: Join Us in Changing Lives At OXB , our people are at the heart of everything we do. We're on a mission to enable life-changing therapies to reach patients around the world—and we're looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful . We're currently recruiting for a Senior Director, Corporate Counsel to join our Legal team on a 12 month fixed-term contract . In this role, you will provide legal advice on corporate and company secretarial matters, partnering with the Chief Legal Officer to protect the Group, enable delivery of its strategy and maintain high standards of legal compliance playing a key part in advancing our mission and making a real difference. Your responsibilities in this role would be, inter alia, to: Assist CLO and Deputy Co Sec with annual report/interims/corporate updates Assist with FTSE listing requirements and FCA filings Assist with Group subsidiary management Assist with corporate governance compliance with best practice Assist with management of debt financing Assist with any corporate transactions, to the extent required Assist with Data Subject Access Requests We are looking for: Qualified solicitor in England and Wales holding a current practising certificate or equivalent professional standing Proven post-qualification experience gained in a leading law firm and/or a complex listed or regulated organisation. UK corporate law expertise with experience in governance, capital markets, M&A, compliance and managing complex legal matters Ability to translate complex legal and regulatory developments into practical, risk-based advice and effective organisational controls. About Us: OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors, the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing development and manufacturing expertise for lentiviral, AAV, adenoviral, MVA and other viral vectors. Building on its viral vector leadership, OXB also supports the development of emerging in vivo therapies through its expertise in vector engineering, manufacturing platforms, and novel envelope technologies. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Why Join Us? ?? Competitive total reward packages ?? Wellbeing programmes that support your mental and physical health ?? Career development opportunities to help you grow and thrive ?? Supportive, inclusive, and collaborative culture ?? State-of-the-art labs and manufacturing facilities ?? A company that lives its values: Responsible, Responsive, Resilient, Respect We want you to feel inspired every day. At OXB, we're future-focused and growing fast. We succeed together—through passion, commitment, and teamwork. Ready to Make a Difference? Collaborate. Contribute. Change lives. We offer: Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient's cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients' cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. TPBN1_UKTJ